Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C15H19Cl2NO |
Molar mass | 300.22 g·mol−1 |
3D model (JSmol) | |
| |
(verify) |
NS-2359 (GSK-372475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials showed the drug was not effective and not well tolerated.[2] The results did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatment of ADHD,[3] phase II having been completed in 2007.[4] A phase I clinical trial exploring the effect of NS-2359 on cocaine-dependent individuals was completed in 2002.[5]
2-Carboxymethyl Esters | |
---|---|
(3,4-Disubstituted Phenyl)-tropanes | |
Arylcarboxy | |
Carboxyalkyl | |
Acyl | |
β,α Stereochemistry | |
α,β Stereochemistry | |
Heterocycles: 3-Substituted-isoxazol-5-yl | |
Heterocycles: 3-Substituted-1,2,4-oxadiazole | |
N-alkyl | |
N-replaced (S,O,C) | |
Irreversible | |
Nortropanes (N-demethylated) |